My ePortfolio Register   

16th International Myeloma Workshop /
Carfilzomib, cyclophosphamide, and dexamethasone in newly diagnosed multiple myeloma

1st - 4th Mar 2017

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 03.03.17
Views: 790

Dr Ralph Boccia - Center for Cancer and Blood Disorders, Bethesda, USA

Dr Boccia speaks with ecancer at the 16th International Myeloma Workshop about the CHAMPION-2 study.

The study evaluated different dose levels of carfilzomib in combination with fixed-dose cyclophosphamide and dexamethasone for the treatment of newly diagnosed multiple myeloma (MM).

Carfilzomib is a selective and irreversible second-generation proteasome inhibitor. 

Carfilzomib (56 mg/m2) twice weekly combined with cyclophosphamide and dexamethasone had manageable toxicity and was effective for treating patients with newly diagnosed MM.

Carfilzomib is also being trialled in relapsed/refractory myeloma, as discussed by Dr Siegel here.

ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence